Progyny (PGNY) Expected to Release Quarterly Earnings on Thursday

Progyny (NASDAQ:PGNY) is expected to be announcing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.3348 per share and revenue of $348.6260 million for the quarter. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:45 PM ET.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same period last year, the company earned $0.17 earnings per share. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Price Performance

Progyny stock opened at $31.48 on Wednesday. The stock has a market capitalization of $2.47 billion, a PE ratio of 40.88, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01. Progyny has a 12 month low of $16.10 and a 12 month high of $33.06. The business has a 50 day simple moving average of $28.82 and a 200-day simple moving average of $23.31.

Progyny declared that its board has authorized a share buyback program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Progyny news, Director Kevin K. Gordon sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $24.99, for a total value of $137,445.00. Following the transaction, the director directly owned 9,318 shares of the company’s stock, valued at $232,856.82. This trade represents a 37.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Cheryl Scott sold 7,439 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $26.39, for a total value of $196,315.21. Following the transaction, the director owned 19,772 shares in the company, valued at approximately $521,783.08. This represents a 27.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,916 shares of company stock worth $939,875 in the last 90 days. Corporate insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PGNY. Royal Bank of Canada grew its holdings in Progyny by 384.8% in the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after buying an additional 10,340 shares in the last quarter. Amundi raised its holdings in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after acquiring an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares during the last quarter. Invesco Ltd. boosted its position in shares of Progyny by 37.4% during the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock valued at $8,342,000 after acquiring an additional 103,253 shares during the last quarter. Finally, Walleye Capital LLC boosted its position in shares of Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock valued at $266,000 after acquiring an additional 780 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Citigroup reiterated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. Weiss Ratings upgraded shares of Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Canaccord Genuity Group raised their price target on shares of Progyny from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Citizens Jmp lifted their price objective on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and an average target price of $33.25.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.